US2009176778A1PendingUtilityA1
Certain nitrogen containing bicyclic chemical entities for treating viral infections
Est. expiryAug 10, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Franz Ulrich SchmitzVincent W-F TaiRoopa RaiChristopher RobertsAli Dehghani Mohammad AbadiSubramanian BaskaranIrina SlobodovJack MaungMartin Neitzel
A61P 43/00A61P 31/12A61P 31/14C07D 471/04A61P 1/16C07D 487/04
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
Claims
exact text as granted — not AI-modified1 . At least one chemical entity selected from compounds of Formula 1:
and pharmaceutically acceptable salts thereof, wherein
W 1 is selected from CR 1 and NR 1 ;
W 3 is selected from CR 3 and NR 3 ;
W 4 is selected from CR 4 and N;
W 6 is selected from CR 6 and N;
W 8 is selected from C and N;
W 9 is selected from C and N;
R 1 is absent or is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 2 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 3 is absent or is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 4 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 5 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 6 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 11 , —CN, —NO 2 , and —C(O)R 12 ;
R 7 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 11 , —CN, —NO 2 , and —C(O)R 12 ;
R 10 and R 11 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R 10 and R 11 , taken together with any intervening atoms, form a ring system selected from optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
R 12 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 13 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 14 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 15 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
R 16 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
provided that
if W 1 is NR 1 and W 3 is NR 3 , then R 3 is absent;
if W 3 is NR 3 and W 1 is NR 1 , then R 1 is absent;
at least one of W 1 , W 3 , W 8 , and W 9 is N;
no more than four of W 1 , W 3 , W 4 , W 6 , W 8 , and W 9 are N; and
if W 1 is N, W 4 is N, and W 6 is CR 16 , then W 8 is not N;
and further provided that the compound of Formula 1 is not
(5-(5-chlorothiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)(3-(3,4-dimethoxyphenyl)-5-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone;
(5-(5-chlorothiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)(3-(2,5-dimethylphenyl)-5-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone; or
(5-(5-chlorothiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)(3-(3,4-dichlorophenyl)-5-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone.
2 . At least one chemical entity of claim 1 wherein R 5 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
3 . At least one chemical entity of claim 1 wherein the compound of Formula 1 is selected from the following compounds:
4 . At least one chemical entity of claim 3 wherein R 5 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
5 . At least one chemical entity of claim 1 wherein the compound of Formula 1 is selected from the following compounds:
6 . At least one chemical entity of claim 5 wherein R 5 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
7 . At least one chemical entity of claim 1 wherein the compound of Formula 1 is selected from the following compounds:
8 . At least one chemical entity of claim 7 wherein R 5 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
9 . At least one chemical entity of claim 1 wherein the compound of Formula 1 is selected from the following compounds:
10 . At least one chemical entity of claim 9 wherein the compound of Formula 1 is selected from the following compounds:
11 . At least one chemical entity of claim 10 wherein the compound of Formula 1 is
12 . At least one chemical entity of claim 9 wherein R 5 is selected from optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl.
13 . At least one chemical entity of claim 1 wherein R 2 is selected from optionally substituted alkyl, —NR 11 S(O) 2 R 14 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(O)OR 13 —C(O)NR 10 R 11 , and —C(O)OR 13 .
14 . At least one chemical entity of claim 13 wherein R 2 is lower alkyl substituted with —NR 10 R 11 .
15 - 18 . (canceled)
19 . At least one chemical entity of claim 14 wherein R 10 and R 11 , together with any intervening atoms, form a substituted 3- to 7-membered nitrogen containing heterocycloalkyl which optionally further includes one or two additional heteroatoms chosen from N, O, S, S(O), S(O) 2 , and P(O), wherein said 3- to 7-membered nitrogen containing heterocycloalkyl is substituted with a group —Y—R 30 and optionally substituted with a second group R 31 , wherein
Y is a bond or is selected from —NR 10 —, —NR 11 SO 2 —, —O—, —S—, —C(O)NR 10 —, and —S(O) 2 R 10 —; R 30 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and R 31 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxy, —OH, —SH, —NO 2 , —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —SO 2 NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —CN, —NR 11 SO 2 R 14 , and —NR 11 CO 2 R 13 .
20 . At least one chemical entity of claim 19 wherein R 10 and R 11 , together with any intervening atoms, form a substituted 3- to 7-membered nitrogen containing heterocycloalkyl which optionally further includes one or two additional heteroatoms chosen from N, O, S, S(O), S(O) 2 , and P(O), wherein said 3- to 7-membered nitrogen containing heterocycloalkyl is substituted with a group —Y—R 30 and optionally substituted with a second group R 31 , wherein
Y is a bond or is selected from —O—, —S—, —C(O)NR 10 —, and —S(O) 2 R 10 —; R 30 is selected from optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and R 31 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxy, —NO 2 , —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —SO 2 NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —CN, —NR 11 SO 2 R 14 , and —NR 11 CO 2 R 13 .
21 - 68 . (canceled)
69 . At least one chemical entity of claim 1 wherein the compound of Formula 1 is chosen from compounds of Table 1, Table 2, and Table 3.
70 . A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of at least one chemical entity of claim 1 .
71 . A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of at least one chemical entity chosen from compounds of Formula 1a
and pharmaceutically acceptable salts thereof, wherein
W 3 is selected from CR 3 and NR 3 ;
R 2 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 3 is absent or is selected from halogen, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(R 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 5 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(R 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 13 , —CN, —NO 2 , and —C(O)R 12 ;
R 16 is selected from hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(R 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 11 , —CN, —NO 2 , and —C(O)R 12 ;
R 7 is selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —OR 15 , —SR 15 , —S(O)R 16 , —S(O) 2 R 16 , —S(O) 2 NR 10 R 11 , —NR 10 R 11 , —NR 11 C(O)NR 10 R 11 , —NR 11 C(S)NR 10 R 11 , —NR 11 S(O) 2 R 14 —NR 11 C(O)OR 13 , —NR 11 C(O)R 12 , —C(NR 11 )NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)OR 11 , —CN, —NO 2 , and —C(O)R 12 ;
R 10 and R 11 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R 10 and R 11 , taken together with any intervening atoms, form a ring system selected from optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;
R 12 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 13 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 14 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R 15 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
R 16 is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
72 - 116 . (canceled)
117 . A method for treating a viral infection in a mammal mediated at least in part by a virus in the flaviviridae family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a pharmaceutical composition according to claim 70 , provided that at least one of R 1 and R 3 is halogen.
118 - 121 . (canceled)Join the waitlist — get patent alerts
Track US2009176778A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.